Angela Sardaro1,2, Fiona McDonald1,3, Lilia Bardoscia4, Konstantin Lavrenkov1,5, Shalini Singh1,6, Sue Ashley1, Daphne Traish1, Cristina Ferrari2, Icro Meattini1,7, Artor Niccoli Asabella2, Michael Brada1,3,8. 1. Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 2. Interdisciplinary Department of Medicine, Nuclear Medicine Unit and Section of Radiology and Radiation Oncology, University of Bari Aldo Moro, Bari, Italy. 3. Academic Radiotherapy Unit, The Institute of Cancer Research, Sutton, United Kingdom. 4. Radiation Therapy Unit, Department of Oncology and Advanced Technology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. 5. Department of Oncology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. 6. Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Department of Radiotherapy, Lucknow, India. 7. Department of Biomedical, Experimental, and Clinical Sciences, University of Florence, Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 8. Department of Radiation Oncology, University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom.
Abstract
BACKGROUND AND PURPOSE: Dyspnea is an important symptomatic endpoint for assessment of radiation-induced lung injury (RILI) following radical radiotherapy in locally advanced disease, which remains the mainstay of treatment at the time of significant advances in therapy including combination treatments with immunotherapy and chemotherapy and the use of local ablative radiotherapy techniques. We investigated the relationship between dose-volume parameters and subjective changes in dyspnea as a measure of RILI and the relationship to spirometry. MATERIAL AND METHODS: Eighty patients receiving radical radiotherapy for non-small cell lung cancer were prospectively assessed for dyspnea using two patient-completed tools: EORTC QLQ-LC13 dyspnea quality of life assessment and dyspnea visual analogue scale (VAS). Global quality of life, spirometry and radiation pneumonitis grade were also assessed. Comparisons were made with lung dose-volume parameters. RESULTS: The median survival of the cohort was 26 months. In the evaluable group of 59 patients there were positive correlations between lung dose-volume parameters and a change in dyspnea quality of life scale at 3 months (V30 p=0.017; V40 p=0.026; V50 p=0.049; mean lung dose p=0.05), and a change in dyspnea VAS at 6 months (V30 p=0.05; V40 p=0.026; V50 p=0.028) after radiotherapy. Lung dose-volume parameters predicted a 10% increase in dyspnea quality of life score at 3 months (V40; p=0.041, V50; p=0.037) and dyspnea VAS score at 6 months (V40; p=0.027) post-treatment. CONCLUSIONS: Worsening of dyspnea is an important symptom of RILI. We demonstrate a relationship between lung dose-volume parameters and a 10% worsening of subjective dyspnea scores. Our findings support the use of subjective dyspnea tools in future studies on radiation-induced lung toxicity, particularly at doses below conventional lung radiation tolerance limits.
BACKGROUND AND PURPOSE: Dyspnea is an important symptomatic endpoint for assessment of radiation-induced lung injury (RILI) following radical radiotherapy in locally advanced disease, which remains the mainstay of treatment at the time of significant advances in therapy including combination treatments with immunotherapy and chemotherapy and the use of local ablative radiotherapy techniques. We investigated the relationship between dose-volume parameters and subjective changes in dyspnea as a measure of RILI and the relationship to spirometry. MATERIAL AND METHODS: Eighty patients receiving radical radiotherapy for non-small cell lung cancer were prospectively assessed for dyspnea using two patient-completed tools: EORTC QLQ-LC13 dyspnea quality of life assessment and dyspnea visual analogue scale (VAS). Global quality of life, spirometry and radiation pneumonitis grade were also assessed. Comparisons were made with lung dose-volume parameters. RESULTS: The median survival of the cohort was 26 months. In the evaluable group of 59 patients there were positive correlations between lung dose-volume parameters and a change in dyspnea quality of life scale at 3 months (V30 p=0.017; V40 p=0.026; V50 p=0.049; mean lung dose p=0.05), and a change in dyspnea VAS at 6 months (V30 p=0.05; V40 p=0.026; V50 p=0.028) after radiotherapy. Lung dose-volume parameters predicted a 10% increase in dyspnea quality of life score at 3 months (V40; p=0.041, V50; p=0.037) and dyspnea VAS score at 6 months (V40; p=0.027) post-treatment. CONCLUSIONS: Worsening of dyspnea is an important symptom of RILI. We demonstrate a relationship between lung dose-volume parameters and a 10% worsening of subjective dyspnea scores. Our findings support the use of subjective dyspnea tools in future studies on radiation-induced lung toxicity, particularly at doses below conventional lung radiation tolerance limits.
Authors: Ellen X Huang; Andrew J Hope; Patricia E Lindsay; Marco Trovo; Issam El Naqa; Joseph O Deasy; Jeffrey D Bradley Journal: Acta Oncol Date: 2010-09-28 Impact factor: 4.089
Authors: M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Tae Hyun Kim; Kwan Ho Cho; Hong Ryull Pyo; Jin Soo Lee; Jae Ill Zo; Dae Ho Lee; Jong Mog Lee; Hyae Young Kim; Bin Hwangbo; Sung Yong Park; Joo Young Kim; Kyung Hwan Shin; Dae Yong Kim Journal: Radiology Date: 2005-02-09 Impact factor: 11.105
Authors: Andrew J Hope; Patricia E Lindsay; Issam El Naqa; James R Alaly; Milos Vicic; Jeffrey D Bradley; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-01 Impact factor: 7.038
Authors: Yvette Seppenwoolde; Katrien De Jaeger; Liesbeth J Boersma; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-01 Impact factor: 7.038
Authors: S L Kwa; J C Theuws; A Wagenaar; E M Damen; L J Boersma; P Baas; S H Muller; J V Lebesque Journal: Radiother Oncol Date: 1998-07 Impact factor: 6.280
Authors: David B Landau; Laura Hughes; Angela Baker; Andrew T Bates; Michael C Bayne; Nicholas Counsell; Angel Garcia-Alonso; Susan V Harden; Jonathan D Hicks; Simon R Hughes; Marianne C Illsley; Iftekhar Khan; Virginia Laurence; Zafar Malik; Helen Mayles; William Philip M Mayles; Elizabeth Miles; Nazia Mohammed; Yenting Ngai; Emma Parsons; James Spicer; Paula Wells; Dean Wilkinson; John D Fenwick Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-28 Impact factor: 7.038
Authors: Laura Cella; Serena Monti; Maria Thor; Andreas Rimner; Joseph O Deasy; Giuseppe Palma Journal: Cancers (Basel) Date: 2021-07-25 Impact factor: 6.639